Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 6, 2020- Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamous non-small cell lung cancer (nsNSCLC) -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an amendment of its...
-
Jan 13, 2020
Curis, Inc (NASDAQ: CRIS) and DarwinHealth, Inc. today announced a multi-year scientific research collaboration to use quantitative, systems biology-based algorithms, CLIA-approved technologies,...
-
Jan 8, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2020, the independent...
-
Jan 7, 2020- Curis to initiate Phase 1a/1b study for CI-8993 in 2020 -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an option and...
-
Dec 6, 2019- Preliminary clinical data on CA-4948 demonstrates anti-cancer activity and favorable safety profile -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing...
-
Dec 6, 2019- 11 patients enrolled to-date in Phase 1 study; combination has been generally well-tolerated -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its...
-
Nov 26, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer...
-
Nov 6, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both fimepinostat and...
-
Nov 5, 2019- Management to host conference call today at 8:30 a.m. ET -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter...
-
Oct 31, 2019
In a release issued under the same headline on October 29th by Curis, Inc., please note that in the first and second paragraphs of the release, financial results will be reported before Nasdaq...